12-09-2019 | Multiple sclerosis | Video
ECTRIMS 2019: Timely and continuous therapy reduces conversion to progressive MS
Pietro Iaffaldano comments on real-world data showing risk factors associated with increased conversion from relapsing-remitting multiple sclerosis to secondary progressive disease (4:31).
Funding for this video was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.